Pacira acquires remaining 81% of GQ Bio for $32M
Pacira (PCRX) announced it has acquired the remaining 81% equity stake of GQ Bio Therapeutics for approximately $32M, net of working capital ...
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local ...
Daily4 天
Govt Panel Directs Serum Institute of India to Add Guillain-Barre Syndrome Warning as Rare ...
The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for ...
OXB to present at the Leerink Partners Global Healthcare Conference
OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global ...
BioWorld4 天
Restoring GJB2 expression rescues hereditary hearing loss
The most common form of hereditary deafness in humans is caused by mutations in the GJB2 gene, which encodes the gap junction protein connexin 26. That regulates the transport of potassium and ...
Taiwan News6 天
Viral Vector Market to Surpass USD 3.10 Billion, Projected 11.5%+ CAGR Through 2030
The Global Viral Vector Market was valued at approximately USD 3.10 billion in 2022 and is projected to grow at a robust CAGR of more than 11.5% during the forecast period 2023-2030. Read the Market ...